Skip to main content

Table 2 Patients receiving caspofungin treatment

From: Caspofungin Use in Daily Clinical Practice for Treatment of Invasive Aspergillosis: Results of a Prospective Observational Registry

Indication for IV caspofungin therapy

Monotherapy

(N= 85) n (%)

Combination

therapy

(N = 18) n (%)

Overall

(N = 103) n (%)

Caspofungin first-line therapy

15 (17.6)

5 (27.8)

20 (19.4)

Caspofungin salvage therapy

70 (82.4)

13 (72.2)

83 (80.6)

   Clinical refractory to first-line antifungal

48 (68.6)

10 (76.9)

58 (69.0)

   Microbiological refractory to first-line antifungal

6 (8.6)

1 (7.7)

7 (8.4)

   Toxicity

   

• Nephrotoxicity to first-line antifungal

2 (2.9)

1 (7.7)

3 (3.6)

• Other toxicity

6 (8.6)

0

6 (7.2)

   Other*

7 (10.0)

1 (7.7)

8 (9.6)

   Not reported

1(1.4)

0

1 (1.2)

  1. *Other reasons include: Severe disease requiring combination therapy, prophylaxis, elevated Aspergillus antigen, empirical therapy, elevated creatinine